Alerts will be sent to your verified email
Verify EmailCAPLIPOINT
Caplin Point Lab
|
Gufic Biosciences
|
Gland Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
51.0 . | n/a | 372.0 . |
Number of ANDA's Approved By USFDA
|
38.0 . | n/a | 325.0 . |
R&D as a % of Total Sales
|
3.52 % | 1.28 % | 4.4 % |
Financials
|
|||
5 yr Average ROE
|
19.84 % | 25.05 % | 12.02 % |
5yr average Equity Multiplier
|
1.15 | 2.22 | 1.15 |
5yr Average Asset Turnover Ratio
|
0.68 | 1.05 | 0.51 |
5yr Avg Net Profit Margin
|
25.35 % | 10.9 % | 20.79 % |
Price to Book
|
6.22 | 5.9 | 3.58 |
P/E
|
31.36 | 57.37 | 42.52 |
5yr Avg Cash Conversion Cycle
|
70.68 Days | 26.94 Days | 69.81 Days |
Inventory Days
|
66.07 Days | 66.86 Days | 118.26 Days |
Days Receivable
|
110.7 Days | 128.09 Days | 99.92 Days |
Days Payable
|
85.23 Days | 163.91 Days | 107.43 Days |
5yr Average Interest Coverage Ratio
|
633.04 | 13.1 | 183.05 |
5yr Avg ROCE
|
24.45 % | 27.25 % | 16.55 % |
5yr Avg Operating Profit Margin
|
31.52 % | 18.45 % | 29.26 % |
5 yr average Debt to Equity
|
0.0 | 0.51 | 0.01 |
5yr CAGR Net Profit
|
17.23 % | 14.26 % | -6.87 % |
5yr Average Return on Assets
|
17.23 % | 11.52 % | 10.65 % |
Shareholdings
|
|||
Promoter Holding
|
70.56 % | 72.52 % | 51.83 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
1.68 % | -2.48 % | -6.04 % |
Change in Mutual Fund Holding (3 Yrs)
|
0.87 % | 2.35 % | 15.13 % |
Caplin Point Lab
|
Gufic Biosciences
|
Gland Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Distribution Channel
|
Distribution Channel
|
-
|
Distribution Channel
|
Manufacturing Break-Up
|
Manufacturing Break-Up
|
-
|
-
|